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Embryonic stem cells (ESCs) possess two unique characteristics: infinite
self-renewal and the potential to differentiate into almost every cell type
(pluripotency). Recently, global expression analyses of metastatic breast and
lung cancers revealed an ESC-like expression program or signature,
specifically for cancers that are mutant for p53 function. Surprisingly, although
p53 is widely recognized as the guardian of the genome, due to its roles in cell
cycle checkpoints, programmed cell death or senescence, relatively little is
known about p53 functions in normal cells, especially in ESCs. My hypothesis
is that p53 has specific transcription regulatory functions in human ESCs
(hESCs) that a) oppose pluripotency and b) protect the stem cell genome in
response to DNA damage and stress signaling. In mouse ESCs, these roles
are believed to coincide, as p53 promotes differentiation in response to DNA
damage, but this is unexplored in hESCs.
To determine the biological roles of p53, specifically in hESCs, we mapped
genome-wide chromatin interactions of p53 by chromatin immunoprecipitation
and massively parallel tag sequencing (ChIP-Seq), and did so under three
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different conditions of hESC status: pluripotency, differentiation-initiated and
DNA-damage-induced. ChIP-Seq showed that p53 is enriched at distinct,
induction-specific gene loci during each of these different conditions. Microarray
gene expression analysis and functional annotation of the distinct p53-target
genes revealed that p53 regulates specific genes encoding developmental
regulators, which are expressed in differentiation-initiated but not DNAdamaged hESCs. We further discovered that, in response to differentiation
signaling, p53 binds regions of chromatin that are repressed but also poised for
rapid activation by core pluripotency factors OCT4 and NANOG in pluripotent
hESCs. In response to DNA damage, genes associated with migration and
motility are targeted by p53; whereas, the prime targets of p53 in control of cell
death are conserved for p53 regulation in both differentiation and DNA damage.
Our genome-wide profiling and bioinformatics analyses show that p53
occupies a special set of developmental regulatory genes during early
differentiation of hESCs and functions in an induction-specific manner. In
conclusion, our research unveiled previously unknown functions of p53 in ESC
biology, which augments our understanding of one of the most deregulated
proteins in human cancers.
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CHAPTER 1 INTRODUCTION
1.1

Pluripotent stem cells

1.1.1 Human Embryonic Stem Cells
Human Embryonic Stem Cells (hESCs) are derived from inner cell mass
of blastocyst-stage embryo [1] and possess two unique properties together:
•

Pluripotency: ability to differentiate into any somatic cell type.

•

Self-renewal: ability to reproduce indefinitely by staying in the same state
(without losing pluripotency characteristics).

Unraveling the molecular mechanisms that preserve ESC properties is
important for understanding development, how the ground state is maintained
and what are the reasons for developmental disorders; studying tissue
differentiation, how the genome is regulated for lineage-specific differentiation;
and generating the necessary knowledge to manipulate hESCs as an
invaluable tool for regenerative medicine. Over the past decade, a global effort
has been underway to deconstruct molecular mechanisms that underlie
pluripotency in order to realize and harness the full potential of hESCs. The
combined results from genetic, biochemical and genomic studies have revealed
an intricate regulatory circuitry of pluripotent state, which contains transcription
factors, chromatin regulators, non-coding RNAs and signaling molecules [2,3,4].
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1.1.2 ESC-specific Transcription factors
Transcription factors can interact with the chromatin through their DNAbinding domains that recognize specific DNA sequences (motifs) [5,6]. These
proteins can induce the transcription of coding/non-coding genes while
repressing the expression of others and are an important part of the regulatory
circuitry. In hESCs, three core (master/key) transcription factors, OCT4
(Pou5f1), SOX2 and NANOG (collectively abbreviated as OSN) act in coherent
circuits to maintain the pluripotent state [7]. Functional studies identified Oct4
and Nanog as master regulators by their unique expression patterns: enriched
in the pluripotent state and reduced as ESCs undergo differentiation [8,9,10,11].
Oct4 and Sox2 form a heterodimer and bind to the DNA hence Sox2 is placed
among the key regulators [12,13], although expression of Sox2 is also observed
in some somatic cell types [14].
An “interconnected autoregulatory loop” emerged from genome-wide
binding studies whereby the master regulators occupy their own promoters and
reciprocally bind to the promoters of other key factors in order to regulate each
other [15]. Oct4:Sox2 and Nanog also bind a major portion of coding/noncoding gene promoters along with several hundred intergenic regions, including
enhancers for pluripotency related genes. Integration of global gene expression
data with OSN binding sites revealed that these factors are involved in
transcriptional regulation of both active and repressed genes [15,16]. The ability
to affect either repression or activation by the same transcription factors may be
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due to context-specific co-factors that are recruited along with these key factors.
One subset of actively expressed targets in ESCs is genes that are essential to
maintain pluripotency and self-renewal where Oct4, Sox2 and Nanog bind
together with co-activators or activating chromatin regulators, e.g. components
of the Trithorax Complex. Transcriptionally silent, OSN gene-targets are
enriched in developmental and differentiation regulators, as well as several
lineage-specific genes. In this case, Oct4, Sox and Nanog repress gene
expression by facilitating the binding of chromatin modifiers such as SetDB1 or
Polycomb complex proteins that mark the chromatin around the regulatory
sequences of silenced genes with repressive histone marks [17].
Several other transcription factors have been shown to play important
roles in the regulation of pluripotency, but not all of these are conserved
between mouse and human ESCs. Sall4 and Tcf3 are shown to target most of
the genes that are bound by the key factors [2,18,19,20]. Other transcription
regulators including Smad1, Ronin, Klf4, PRDM14, Tbx3, Esrrb and Trim28 are
also implicated in maintaining pluripotency and controlling ESC state
[2,20,21,22].

1.1.3 Chromatin regulators
The eukaryotic genome is wrapped around highly conserved histone
protein bundles (nucleosomes) to achieve compression of this long string of
DNA into the nucleus, creating a higher-order DNA-protein complex called
chromatin [23]. Nucleosome structure around a certain region has been shown
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to affect the accessibility of underlying genomic elements (promoters,
enhancers) thereby influences gene expression, DNA replication, DNA repair
and others [24]. Several studies showed that certain sets of chromatin
modifying enzymes contribute to the stability of pluripotency: whereas, others
influence the establishment of conditions favorable to differentiation [25,26,27].
These

chromatin

dependent

regulators

nucleosome

include

remodeling

histone-modifying
complexes,

enzymes,

DNA

ATP-

(de)methylation

complexes and higher order chromatin organizers, such as CTCF and cohesion
[4,28].

1.1.3.1 Histone-modifying enzymes
Tails emanating from histone proteins in the nucleosomes are subjected
to

certain

methylation,

reversible

post-translational

acetylation,

modifications

phosphorylation

and

(PTMs)

ubiquitination

such

as

[29,30].

Combinations of the histone PTMs influence numerous molecular processes;
therefore, complexes that are “reading”, ”writing” and “erasing” certain
modifications have significant roles in ESC biology [31,32,33].
One of the key features of ESCs is the presence of bivalent histone
modifications at the regulatory sites of certain genes [34]. Genes encoding
developmental and lineage-specific regulators are held in a “poised” state by
bivalent histone modifications, defined as concomitant active histone mark
histone H3 lysine 4 tri-methylation (H3K4me3) and repressive histone mark
histone H3 lysine 27 tri-methylation (H3K27me3) on the same chromatin region.
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These poised genes are silent in pluripotent cells but rapidly activated in
response to signals that induce differentiation by changing the histone PTM
status near promoters [35,36,37,38]. In general, Trithorax group (TrxG) proteins
deposit H3K4me3 marks at promoters, and promote the transcription of active
genes [39]. On the other hand, polycomb group (PcG) proteins catalyze
deposition of H3K27me3 and, when present as a bivalent PTM prevent the
transcription of developmental or key signaling genes in order to maintain a
pluripotent state [40,41,42].

Several studies have shown that depletion of

certain TrxG complex proteins or subunits of the PcG complex, such as PRC1
and PRC2, leads to defects in pluripotency maintenance and proper
differentiation, supporting their importance in ESCs [43,44,45]. Genome-wide
mapping comparisons revealed high co-localization of core pluripotency factors
with PcG proteins [17,42]; moreover, Oct4 is reported to interact with
components of TrxG and PcG complexes [46]. Taken together, these findings
suggest an interconnection between core transcription factors and histonemodifying enzymes in order to maintain pluripotency. As ESCs differentiate into
a certain lineage, specific developmental factors are induced by mechanisms
that retain the active histone mark (H3K4me3) while removing the repressive
histone mark (H3K27me3). In parallel, non-induced genes, such as regulators
of cellular lineages that are not induced, tend to lose their “poising”, active
histone modifications and acquire more H3K27me3 mark, which provides a
mechanism for how bivalent domains help to establish ESC plasticity [38,47]
(Figure1).
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In addition to H3K27me3, histone H3 lysine 9 tri-methylation (H3K9me3)
is another important repressive histone modification for ESCs [48]. SetDb1,
G9a and Suv39h1 are involved in catalysis of H3K9me3, which has been
shown to repress diverse developmental regulators in the pluripotent state
[49,50,51]. Thus, various histone modifiers are involved in gene silencing of
several developmental regulators in ESCs.
Histone acetyltransferases (HATs) are also implicated in the regulation of
pluripotency and lineage-specific differentiation. The Tip60-p400 complex,
which catalyzes histone H4 acetylation, also targets most of the Nanog binding
sites and based on functional screens emerged as an ESC identifier [52].
Another HAT, p300, together with the presence of the histone H3 lysine 4
mono-methylation (H3K4me1) mark, has been associated with enhancer
regions and co-localizes significantly with key transcription factors at promoter
distal regions of genes in ESCs [53]. Similar to ESC promoters, enhancers may
also exist in poised (marked with H3K27me3) or active states (marked with
H3K27ac)

[54,55].

Although

the

mechanism

remains

elusive,

during

differentiation poised enhancers are converted to active ones, a process that
requires HAT enzyme activity to deposit acetylation on histone H3 lysine 27 in a
lineage-specific manner, and consequently help to establish tissue-specific
gene expression programs [56,57,58].
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Figure 1. Bivalent chromatin domains help to establish embryonic stem
cell plasticity. Reprinted by permission from Elsevier: Current Opinion in
Genetics & Development, copyright (2008) [31].
Promoter of developmental transcription factor, Otx2 (neural-specific
developmental factor) is marked by bivalent chromatin marks (H3K4me3 and
H3K27me3) and transcriptionally poised in ES cells. In neural progenitor cells,
Otx2 is transcribed and promoter is only associated with activating mark
H4K3me3 while repressive histone mark H3K27me3 is selectively removed. In
embryonic fibroblast cells, the expression of Otx2 is permanently repressed as
a result of remaining H3K27me3 mark.
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1.1.4 Non-coding RNAs
A number of genome-wide transcription studies inferred that the majority
of the mammalian genome is transcribed, and many of these transcribed
regions do not encode for a protein [59]. Subsequent studies revealed some of
the biological functions of these pervasive non-coding transcripts [60].
Regulatory roles of non-coding RNAs (ncRNAs) in bio-molecular processes
include repeated elements silencing, X-chromosome inactivation, polycomb
repression and regulation of embryogenesis at different stages [61]. A diverse
group of ncRNAs transcripts have been postulated to control, in part, the ESC
state, including microRNAs (miRNAs) and large intergenic ncRNAs (lncRNAs)
[62].
miRNAs are small ncRNAs (~22 nucleotide long) that are involved in
post-translational

mRNA

silencing

by

base

pairing

to

complementary

sequences of their target RNAs in order to regulate a gene-expression program
in cells [63,64]. Lack of miRNA biogenesis pathway components (Dicer and
DGCR8) in mouse ESC results in defects in differentiation and decreased
proliferation rates, which demonstrates the importance of this particular ncRNA
family for the regulatory circuitry of pluripotent state [65,66]. Two key themes
emerged from a study by Marson et al., which revealed how miRNAs integrate
into that regulatory circuitry[67]:
1) Key transcription factors induce expression of miRNAs that are critical
to fine-tune the mRNA levels of ESC-related genes that maintain pluripotency
and those that facilitate the rapid degradation of ESC transcripts during
differentiation and establish cell state transitions [68,69]. The cluster of mir-2908

295 constitutes a big portion of such miRNAs [70]. Members of this cluster
contain seed sequences that can recognize mRNA of proliferation-related or
epigenetic modulator genes; and, therefore, are involved in maintenance of
pluripotency.
2) In the same fashion as lineage-dependent gene regulation, with the
help of repressive chromatin regulators SetDB1 and PcG complexes, key
transcription factors poise the expression of certain miRNA families. These
miRNAs are up-regulated during lineage-programming and inhibit several key
genes that are required to maintain pluripotency [71]. For example, human miR145 can target and repress pluripotency specific genes, including OCT4, SOX2,
and KLF4. OCT4 binds to up-stream regions of the miR-145 promoter and
poises its expression in hESCs to establish an “irreversible positive feedback”
loop that helps to control the balance between pluripotency and differentiation
[72].
Discovered lnRNAs are defined as intergenic transcripts longer than 200
nucleotides in length with little potential for coding functional proteins and
revealed by a specific chromatin signature: a combination of promoterassociated H3K4me3 and RNA Polymerase II (PolII) elongation mark histone
H3 lysine 36 tri-methylation (H3K36me3) [73,74]. They can play important roles
in numerous cellular processes, including participation in a pluripotencydifferentiation balance with some lncRNAs favoring pluripotency and others
differentiation [75,76]. An intriguing study by Guttman et al. revealed that,
majority of lncRNA regulatory regions are bound by core transcription factors in
ESCs [77]. This suggests that, like protein coding genes, lncRNAs are also
9

regulated by core pluripotency factors to maintain the ES cell state. Additionally,
in the same study, the functional relevance of 226 lncRNAs were assessed by
RNA interference experiments in mouse ESCs and supported a model where
impairment of lnRNA expression influences proper ESC maintenance as well as
differentiation. Intriguingly, RNA immunoprecipitation experiments indicated that
~75% of lincRNAs were bound to at least one chromatin regulatory complex,
such as PcG and/or LSD1-histone demethylase proteins, substantiating the
hypothesis that lncRNAs may function as modular scaffolds to bring different
proteins or complexes together and reinforce the recruitment and stabilization of
chromatin complexes during development and pluripotency [78,79,80].

1.1.5 Signaling mediators of the ESC state
Signal-transduction pathways are involved in regulation of various
cellular processes, and perturbations in a signaling cascade may lead to severe
abnormalities, including initiation or progression of cancer [81]. As a part of an
effort towards deconstructing regulatory mechanisms of ESCs and development,
numerous signaling pathways were scrutinized in detail and divided into intrinsic
ones, which maintain an ESC state, and extrinsic signaling, which initiates
lineage-specific differentiation [22,82,83].

1.1.5.1 Signaling pathways that maintain pluripotency
Extrinsic signaling pathways that impinge on pluripotency are distinct in
human ESCs from those in mouse ESCs [84,85]. LIF and BMP pathways are

10

related to sustain mouse ESC state; whereas, transforming growth factor-β
(TGF-β) signaling is one of the key pathways that maintain pluripotency in
hESCs [86]. Activin and nodal proteins are members of the TGF-β family of
ligands and suppress hESC differentiation, in part, by blocking BMP4
expression [87]. Additionally, Activin/nodal proteins can activate effector
transcription factors (SMAD2/3), which in conjunction with an extracellular
protein FGF2, up-regulate expression of core transcription factors NANOG and
OCT4 to support hESC self-renewal [88,89,90]. Even though, WNT-mediated
signaling has been implied in short-term pluripotency maintenance, the
underlying

mechanisms

remain

uncertain

[91].

In

summary,

several

extracellular signaling pathways play critical roles in the regulation and
maintenance of ESC state.

1.1.5.2 Differentiation-related extrinsic signaling pathways
Pluripotent ES cell can give rise to three primary germ layers: endoderm
(pancreas, lung, gut), ectoderm (nerve, skin) and mesoderm (muscle, blood),
which are initiated by different extrinsic signaling pathways. Specific small
molecules and receptor ligands either alone or in combination cocktails are
used to differentiate ESCs into a specific lineage. In this study, we utilized
Retinoic Acid (RA) signaling pathway as a model system to study early lineagespecific (neuro-ectoderm in particular) differentiation of hESCs.
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1.1.5.2.1 Retinoic Acid signaling
Active metabolites of Vitamin A are collectively called retinoids, and they
have been implicated in regulation of various biological processes [92]. For
animals, dietary intake is the only source of retinoids since de novo synthesis
mechanisms for these molecules do not exist. Several enzymes are involved in
retinoid uptake regulation in mammalian systems. Retinoids are first converted
into retinaldehyde by oxidization enzymes called alcohol dehydrogenases
(ADHs). Retinaldehyde dehydrogenase (RALDHs) enzymes catalyze the
second step (oxidization of retinaldehyde), from which Retinoic Acids (RAs) are
produced [93]. RALDH2 is the sole enzyme responsible for embryonic uptake of
RAs that, when deleted in mice, results in lethality, which signifies the
importance of RAs during mammalian embryogenesis [94]. Given their
significance in development, distribution patterns of RAs are strictly controlled
by cytochrome P450 26 subfamily proteins that convert RA into less stable
byproducts which are rapidly degraded in tissues that should not receive RA
signaling [95].
Once transported inside the cell, RAs are shuttled to the nucleus with the
help of specialized-proteins, such as CRABP2 (cellular RA-binding proteins). In
the nucleus, RAs form a new complex by binding to retinoic acid receptors
(RARs) and retinoid X receptors (RXRs), which when activated by RA-binding
form heterodimers and bind to specific DNA motifs known as RA-response
elements (RAREs). Following DNA binding of the RXR/RAR complex, a number
of co-activators, e.g. NF1, together with ATP-dependent chromatin remodeling
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complexes are recruited to RAREs in order to facilitate transcription of lineagespecific RA-responsive genes [96].
Early studies demonstrated that RA-treated ESCs undergo neuroectodermal lineage differentiation, which leads to the formation of neural
progenitor cells [97]. Numerous RA target genes have been identified so far,
including developmental transcription factor HoxA1, suggesting that activation
of RA signaling drives ESCs towards neural-lineage development by inducing
expression of a particular set of lineage-specific developmental factors [93,98].
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1.1.6 Induced Pluripotent Stem Cells
A groundbreaking experiment in 2006 performed by Yamanaka’s lab –
for which Dr. Yamanaka eventually was awarded the 2012 Nobel Prize in
Physiology or Medicine - demonstrated that retroviral-mediated transfer of four
transcription factors (Oct4, Sox2, Klf4 and c-Myc) can reprogram differentiated
mouse embryonic fibroblasts to an ESC-like state, known as induced pluripotent
stem cells (iPSCs) [99]. Successive studies showed that similar reprogramming
could be achieved by the transduction of the same or a modified set, e.g. Lin28
as substitute for Klf4 and c-Myc as a dispensable factor, of transcription factors
in human differentiated cells [100,101,102]. Similarly, some ncRNAs, such as
lincRNA-regulator of programming (linc-RoR) [103], or miRNAs, miR-294 and
miR-295 [104], can also be used to enhance reprogramming efficiencies.
Notably, in vivo studies elucidated the striking morphological and
biological similarities between ESCs and iPSCs, including the most stringent
tests of pluripotency: differentiation into multiple germ layers and formation of
teratomas [99]. Comparison of the genome-wide binding of core transcriptional
factors demonstrated that localization of these factors significantly overlaps
between hESCs and hiPSCs, except at some heterochromatin regions marked
by H3K9me3 (named as OSKM-DBRs) [105,106]. Although some studies
indicate that reprogramming fails to completely erase the epigenetic memory of
the cell of origin [106], limited but consistent genome-wide transcriptional and
chromatin-based variations, mainly bivalent modifications, H3K4me3 and
H3K27me3, are observed between hESCs and hiPSCs [107] (Figure2). Taken
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together, shared similarities by ES and iPS cells increase the hopes that human
iPS cells could one day be used as therapeutic agents in immune-matched
patient-specific regenerative medicine practices [108].
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Figure 2. Genome-wide bivalent chromatin modification maps show
significant similarities between human iPS and ES cells. Reprinted by
permission from Elsevier: Cell Stem Cell, copyright (2010) [107].
A. Aggregate plot show H3K4me3 enrichment profile for all RefSeq genes in ES
cells (solid blue) and iPS cells (dashed blue). The arrow indicates transcription
start site (TSS) and direction of transcription of the average.
B. Heatmap depicts the density of H3K4me3 mark (blue) around all Refseq
genes promoters – genomic region from -4.5kb to +4.5kb relative to the TSS is
shown. Gene order was determined by highest average ChIP-Seq density in ES
cells and arranged from highest to lowest density.
C. Aggregate plot show H3K4me3 enrichment profile for all RefSeq genes in ES
cells (solid blue) and iPS cells (dashed blue).
D. Heatmap depicts the density of H3K27me3 mark (green) around all Refseq
genes promoters – genomic region from -4.5kb to +4.5kb relative to the TSS is
shown.
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1.1.7 ESC-specific gene expression signatures in human cancer
Cancer cells exhibit molecular and biological traits that resemble some
hallmarks of stem cells, including high proliferation rate, self-renewal and even
lack of differentiation since some aggressive tumors are present in an
undifferentiated state [109]. Recent studies showed that ES cell-like gene
expression signatures are shared among different human cancers, which could
account for some of the reported similarities between cancer and ES cells [110].
One of the earliest studies that compared the underlying gene expression
programs of ESCs and epithelial cancer cells revealed an evolutionary
conserved (between mouse and man) ESC-like transcriptional signature, which
is activated in various human epithelial cancers yet suppressed in normal cells
[111]. Furthermore, Weinberg and colleagues have shown that poorly
differentiated human tumors exhibit transcription of ES-cell-specific genes along
with repression of PcG complex (PRC2, Eed and Suz12) target genes [112]
(Figure3). In contrast, a more recent study argued that recapitulated ESC-like
gene expression signatures in cancers are mainly due to activation of proproliferation factor c-Myc in human tumors but not the core transcription factors
[113]. Although, the idea is compelling, since c-Myc locus amplification is one of
the most frequent copy-number alterations in human cancers [114], it is unclear
how c-Myc can be solely responsible for the activation of a core ESC program
during tumor initiation, considering that c-Myc is not strictly required for iPS cell
generation or reprogramming [102]. Overall, accumulated evidence indicates
that an ES cell-like gene expression program is positively correlated with poorly
differentiated tumors (histologically graded), increased risk of metastasis and
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decreased survival rate in human patients.

Figure 3. High-grade human breast cancers display ES-cell-specific gene
expression signature. Reprinted by permission from Macmillan Publishers
Ltd: Nature Genetics, copyright (2008) [112].
1,211 breast cancer samples have been investigated (columns). Red/green
colors indicate significantly over- or under expressed gene sets, respectively.
Bottom bars (brown) indicate individual tumor annotations - where available for ER status (positive or negative), grade (1,2 or 3), and tumor size (S – tumor
smaller than 2cm, L – tumor larger than 2cm).
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1.2

p53 and Pluripotency
Transcription factor p53 drives expression of an array of target genes in a

cellular-context and stress-stimuli specific manner. p53’s function as a tumor
suppressor has long been recognized, hence it is aptly named as the “guardian
of the genome”. It functions as a tumor suppressor by promoting apoptosis and
regulating cell proliferation, primarily by cell-cycle arrest, in response to various
stress

signals,

such

as

oncogenic activation,

tumor-suppressor

gene

inactivation, genotoxic damage exposure and loss of normal cell-cell contacts.
Thus, p53 prevents an accumulation of genomic instability, which is one of the
major causes of cancer formation [115]. However, p53’s contribution to
numerous other cellular processes has only recently been appreciated,
including its functions in development and differentiation [116].

1.2.1 p53 acts as barrier to somatic cell reprogramming
The

seminal

study

by

Takahashi

and

Yamanaka

on

nuclear

reprogramming offers great possibilities for regenerative medicine, as
generation of patient-specific iPS cells becomes feasible, in addition to the
ability to study mechanisms of development and disease in these cell systems.
However, the shortcomings of the original method, namely, an inefficient
reprogramming rate (1-3%) and slow kinetics of iPSC generation (as long as
several weeks), are major drawbacks to the clinical use of reprogrammed cells.
These challenges led researchers to consider whether proteins that acted as
barriers and limited somatic cell reprogramming were expressed in
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differentiated cells.
Notably, five simultaneous reports showed, by various experimental
approaches, that depleting p53 or inhibiting p53-dependet pathways to disrupt
p53 functions dramatically increases the reprogramming rate (as much as
80%) and accelerates the kinetics (as early as 3 to 5 days) of iPSCs
generation [117,118,119,120,121]. Although the obtained results were exciting
and encouraging, several concerns have arisen regarding inhibition of a crucial
tumor suppressor during reprogramming [122,123].

One of the previously

mentioned five studies, Hong et al., observed that mice generated by partially
using p53-deficient iPS cells were viable but these mice eventually developed
tumors [117]. In addition, Marion et al. reported increased genome instability
and abnormal telomere shortening in p53-deficient iPS cells [120]. Although,
the use of oncogenic reprogramming factors, such as c-Myc and Klf4 or
retroviral-mediated infections may be potential explanations for the induction of
p53 and its activity as a barrier to reprogramming, less oncogenic
reprogramming techniques, which exclude oncogenic factors from the
reprogramming cocktail or using different transfection methods, still lead to a
p53-mediated cell-cycle arrest of a majority of cells during reprogramming. This
suggests that p53’s function during creation of iPS cells could extend beyond
its responsibility to safeguard the genomic integrity during oncogenic stress
[124].

1.2.2 p53-inactivated cancers display plasticity and loss of differentiation
Although cancerous cells exhibit striking differences between individuals
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or due to the tissue origin of the disease, most of them share one general
deficiency: p53 loss-of-function, which underscores the importance of p53 in
maintaining cellular integrity. Given p53’s prominent role to restrain cellular
reprogramming and the gene expression signatures shared between cancers
and ES cells, it is reasonable to ask whether there is a positive correlation
between p53 inactivation and acquisition of a stem-like state.
In two separate studies, Levine and associates surveyed global gene
expression in metastatic breast and lung cancers [125], or prostate tumors
[126], and demonstrated that cancers that are mutant for p53 function exhibit
an ESC-like expression program that correlated with worse overall survival
rates for patients. A similar association was previously observed at a molecular
level in poorly differentiated thyroid cancers [127], in lung cancers [128] or in
acute myeloid leukemia progenitors [129]. Consistent with these findings, it has
also been shown that expression of p53 induces differentiation of leukemiaderived cells K562 cells [130].
Taken together, a better understanding regarding the pathways that drive
dedifferentiation in p53-inactivated cells or the precise mechanism of how p53
can function to favor differentiation is required to enhance efficiency of iPS cell
production without jeopardizing genomic stability of those cells. Additionally, a
better understanding of how tumor cells acquire cellular plasticity after p53inactivation may lead to development of more potent and targeted therapeutic
treatments.
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1.2.3 p53’s function in human ES cell differentiation
Tumor suppressor p53 has been implicated in limiting the self-renewal of
stem cells, specifically in mouse ES cells by suppressing core pluripotency
factor Nanog [131] or by activating developmental Wnt-signaling [132]. These
findings led to the hypothesis that p53 imposes differentiation of mouse ESC
as a tumor-suppressive mechanism in response to DNA damage [133]. In
addition to being regulated by distinct extrinsic signaling pathways, multiple
studies suggest there are fundamental differences between mouse and human
ES cells at the basic mechanisms of transcription factor function. As an
example, even the core transcription factor binding sites show significant
differences: only 5% of the most enriched OCT4 and NANOG binding sites in
hESC are present at homologous regions in mice [134,135]. Additionally,
hESCs contain one inactivated X-chromosome thereby present in a “primed”
state for differentiation, while mESCs are in a more primitive, “naïve” state,
which maintain two active X-chromosomes [136,137]. Further understanding of
the earliest stages of human embryonic development is needed to resolve
such controversies [138].
Unlike differentiation in mouse ES cells, p53-dependent cell cycle arrest
is observed in human ES cells in response to DNA-damage [139], which
suggests that different stress-specific functions of p53 exist between mouse
and man. Recent work from our laboratory revealed that p53 plays a significant
role during retinoic acid-mediated differentiation of human ESCs. Depletion of
p53 results in inefficiencies during differentiation since the majority of the cells
maintain higher levels of OCT4 and NANOG expression even after several
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days of RA treatment. This suggests that p53 is an important factor for efficient
differentiation of hESCs [140]. Human ESCs stably expressing wild-type p53
under TET-inducible promoter underwent differentiation even in absence of
Retinoic Acid. However, the same effect was not observed when a mutated
form of p53, p53R175H, which is incapable of binding to DNA, is ectopically
expressed. This suggests that p53 promotes hESC differentiation by binding to
DNA and functioning as a transcription factor to activate or repress targets
gene expression.
Further analyses revealed that, in response to RA, p53 is enriched at
the promoter of one of the key p53-effector genes, p21 or CDKN1A and
induces its expression. This is significant since higher levels of p21 results in
the accumulation of hESCs in G1-phase of cell cycle, which promotes
differentiation. These actions of p53 in hESCs are in complete contrast to its
roles in mouse ESC differentiation, where it represses Nanog expression by
directly binding to its promoter [131]. Lengthening of the hES cell cycle and
impeding rapid cell divisions not only limit self-renewal but also facilitate the
programs that induce differentiation [141]. Additionally, p53 also activates
expression of specific micro-RNAs, miR-145 and miR-34a, which repress
expression levels of core pluripotency factors OCT4, SOX2 and KLF4 and thus
prevent partially differentiated hESCs from backsliding to pluripotency.

1.3

Genome-wide protein-chromatin interaction studies
Cell fate and development are established through an intricate network

that regulates gene expression programs in a certain tissue at a given time.
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Understanding the nature of

DNA-protein

interactions and epigenetic

modifications is crucial for deciphering the codes of the underlying gene
regulatory networks [5]. Several approaches have been devised to identify
genome-wide locations of transcription factor binding and histone modifications
[142]. Chromatin immunoprecipitation (ChIP) is a powerful method to purify
DNA fragments that are associated with a particular transcription factor (TF) or
a post-transcriptionally modified histone. Initial high-throughput screens used
ChIP and predesigned microarrays, a method known as ChIP-chip, by
hybridizing fluorescent-labeled, ChIP-antibody precipitated fragments of DNA to
homologous oligomers of DNA fixed to substrates [143]. Although, whole
genome tiling arrays can be used to screen entire genome in a ChIP-chip study,
this method requires several chips per condition, therefore is infeasible and not
cost-effective for mammalian genome studies [144].
Advancements in next-generation sequencing technology, where the
antibody-bound chromatin fragments obtained from a ChIP experiment are
directly subjected to deep sequencing of DNA, made identification of DNAprotein interactions more comprehensive [145]. Chromatin immunoprecipitation
followed by sequencing (ChIP-seq) is advantageous over the ChIP-chip method
in several ways: it provides better resolution and unbiased genome coverage,
obtained results contain fewer artifacts and it requires smaller amounts of
starting material [146,147]. Numerous computational tools have been
developed to pinpoint the precise location of a protein of interest’s binding site
within the genome of the studied organism and to annotate or compare the
obtained data for downstream analyses [147].
24

Some common steps of ChIP-Seq data analysis pipeline can be listed as:


Read mapping – As a first step, obtained sequenced ChIP fragments (tags)
are aligned onto the genome with the help of any available short-read
mappers (i.e. Bowtie, BWA or Illumina’s ELAND software).



Identification of significantly enriched regions (Peak calling) – Once
alignment is done, the next step is to identify genomic sites where the
obtained reads are enriched significantly higher than expected by chance.
Although ChIP-seq offers less technical artifacts, it is still subject to some
inherent biases due to the experimental protocols (antibody specificity),
sequencing technology (non-specific noise) or the genomic structure
(regional GC bias, open chromatin regions tend to precipitate more easily).
Thus generating input control data is a vital step for augmenting this
identification step.



Down-stream analysis – Several subsequent analyses can be performed
based on the purpose of the study, such as identifying location of the
enriched regions on the genome relative to any known genomic features,
motif discovery or incorporating gene expression data to identify potential
function of studied transcription factor.

1.4

Hypothesis, specific aims and rationale

My hypothesis is that p53 regulates transcription of a signal-specific subset of
genomic targets in hESCs that a) oppose pluripotency and b) protect the stem
cell genome in response to differentiation and DNA damage.
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Specific Aims
I tested this hypothesis by the following specific aims:
Specific Aim 1) To characterize p53’s genome-wide binding profiles in
DNA-damaged induced hESCs.
Specific Aim 2) To characterize p53’s genome-wide binding profiles in
differentiating hESCs and their potential functions.
Specific Aim 3) To compare p53-enriched sites with ES cell landmark
signatures.

Rationale: p53 protein levels are elevated to comparable levels in DNA
damage-induced hESCs and differentiation-initiated hESCs. Although similar
abundance of p53 is observed under these conditions, cellular outcomes are
strikingly different where DNA damage causes cells to arrest or undergo
apoptosis and RA induces cells to differentiate and change their molecular
signature. Our previous data showed that p53’s DNA-binding ability is essential
for its role of promoting hESCs differentiation. Thereby, p53’s binding
preferences could be the dictating factor for the different readouts and
identification of those p53 binding sites may reveal which subset of target genes
are responsible for each specific response.
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CHAPTER 2 MATERIAL AND METHODS
2.1

ChIP-Seq Analysis

2.1.1 Sequencing and read alignment
Sequencing of p53-bound DNA was performed at the Bioinformatics
Core of the Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. p53bound DNA (~10 ng) was purified by PAGE to obtain 100–300 bp fragments
and sequenced on an Illumina Solexa GAII sequencer. Sequencing of
chromatin marks H3K4me3 and H3K27me3 ChIP DNA was performed at the
MD Anderson DNA Analysis Facility. DNA associated with modified histones
(~10 ng) was purified by PAGE to obtain 100–300 bp fragments and sequenced
on an Illumina HiSeq2000 sequencer. Sequence reads (36 base pair long)
derived from Illumina sequencers were aligned to the NCBI Build 36 (UCSC
hg18) human genome using ELAND software (Illumina) to produce uniquely
matched reads with up to two mismatches per read allowance.
2.1.2 Peak calling
Enriched regions for each condition were normalized to input DNA and
detected

by

MACS

version

1.4.0

http://liulab.dfci.harvard.edu/MACS/)

(Model

[148]

with

based
a

analysis

p-value

of

ChIP,

threshold

of

enrichment of P < 1.00 E-8 for damage and differentiation datasets; however, a
higher cut-off was used for untreated dataset because of the low throughput
and high signal-to-noise ratio in this experiment - P < 1.00 E-10. Non-default
shift and bandwidth sizes were used for each dataset based on average
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precipitated

DNA

fragments

length

in

each

case.

Wiggle

files

(http://genome.ucsc.edu/goldenPath/help/wiggle.html) were generated using
the same sequence files and density of reads per base pair was calculated in a
25bp window and later normalized to 10 million reads per sample.
Peaks share at least one base under their enriched regions called as
overlapped between different conditions. BEDTools functions (intersectBed or
windowBed)

were

used

to

perform

overlapping

sites

analyses

(http://code.google.com/p/bedtools/) [149].
The distance between unique peaks in each condition was measured
using a gradually increasing window and determining the unique peaks summits
coinciding in the same window. Obtained numbers were plotted and pie charts
were generated by ratios of overlapping versus non-overlapping summits for a
certain window length.

2.1.3 Conservation of binding sites
PhastCons conservation scores for 44 vertebrate species were
downloaded from UCSC website (which contains base-by-base conservation
scores based on a statistical model called phylogenetic hidden Markov model
[150]) and individual chromosome files were merged into a single wiggle file
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/phastCons44way/vertebrate/
). Aggregate plots for conservation scores across (-3kb to +3kb) enriched sites
were generated using the Sitepro version 0.6.6 program under CEAS
(http://liulab.dfci.harvard.edu/CEAS/) [151] with 100bp resolution.
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2.1.4 Motif analysis
Both de-novo motif discovery and known motif matching were performed
using the MEME software suit. The sequences of the p53-peak regions were
extracted in FASTA format and used as input for the MEME-ChIP pipeline,
which is specifically designed to discover associated motifs in large sets of DNA
sequences (http://meme.nbcr.net/meme4_6_1/memechip-intro.html) [152]. The
pipeline runs MEME (good for long motifs) [153], DREME (good for short
motifs) [154] for over-represented DNA-sequences in input, and AME (Analysis
of motif enrichment) to search and compare the motifs that are discovered by
MEME and DREME in the existing motif databases [155]. Briefly, zero or one
motif per sequence was searched with the motif lengths between 6-30 base
pairs, around 600bp of the peak summits and outputs for each dataset are
shown with a p-value cut-off less than 1.00 E-10.
SeqPos motif

discovery program in Cistrome analysis pipeline

(http://cistrome.org/ap/)

[156]

was

also

performed

for

motif

discovery

underneath enriched sites (around 400bp of the peak’s center) in each
condition by using cistrome’s curated motif database.

2.1.5 Identifying target genes of p53-bound sites
Human RefSeq gene information was obtained from UCSC table browser
for

human

genome

hg18

assembly

(http://genome.ucsc.edu/cgi-

bin/hgTables?command=start) [157]. Fold enrichment analysis over the
randomized binding sites was performed as previously described [158]. Genes
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with a nearby p53 peak 10Kb up/down-stream of transcription start sites were
designated as targets.

2.1.6 Annotation of p53-target genes
Gene Ontology analyses for each set of target genes were performed
using DAVID (http://david.abcc.ncifcrf.gov/) [159]. Developmental transcription
factors were obtained from the HUGO Gene Nomenclature Committee at the
European

Bioinformatics

Institute’s

website

(http://www.genenames.org/genefamily.html) [160], previously published study
annotations

(Supplementary

table

S11

in

Lee

et

al.

http://www.sciencedirect.com/science/article/pii/S0092867406003849#mmc12)
[17] and NCBI’s Gene database (http://www.ncbi.nlm.nih.gov/gene). Each dot
shown represents a member of a particular family only if the gene’s ontology
terms (GO - Biological Process and Molecular Function) entail transcription or
DNA binding and also development or differentiation. Gephi (http://gephi.org/)
graphic visualization software was used to generate network graph.
INTERPRO protein domain analysis was performed using Genomic
Regions Enrichment of Annotations Tool or GREAT (great.stanford.edu) [161].
Peak files (Differentiation-specific, Damage-specific and conserved p53
bindings sites) were imported into GREAT by setting a gene association rule as
a single gene within 10 kb ranges of binding sites. The top five categories by
binomial p-value scores are shown.
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2.1.7 Integration core ES cell transcription factor binding data
ChIP-Seq datasets of OCT4 (GSM518373) and NANOG (GSM518374)
were obtained from GEO database (http://www.ncbi.nlm.nih.gov/geo/) [162].
Raw sequences were re-analyzed with MACS version 1.4.0. Obtained peaks
were used for overlap analysis and circular plot. Circos (http://circos.ca/) [163]
was used to visualize p53, OCT4, NANOG and H3K27me3 around four HOX
clusters. H3K27me3 ChIP-Seq data was obtained from UCSC genome
browsers’

ENCODE

project

website

(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC/wgEncodeBroa
dChipSeq/) [164].
Wiggle files were generated by using the obtained sequence files and
density of reads per base pair was calculated in a 25bp window and later
normalized to 10 million reads per sample and used for aggregate plots which
were generated by using Sitepro program in CEAS toolkit. Normalized wiggle
files were used to generate a density plot, using the heatmap tool in the
Cistrome analysis pipeline (http://cistrome.org/ap/) [165]. K-means clustering (5
cluster) was applied to the intensity signals of p53-Damage, p53-Differentiation,
OCT4 and NANOG that were extracted around (-500 to +500bp) the p53condition-specific genomic regions.
Peaks share at least one base under their enriched regions called as
overlapped between different datasets (OCT4, NANOG, p53-Damage, p53Differentiation). BEDTools functions (intersectBed or windowBed) were used to
perform overlapping sites analyses (http://code.google.com/p/bedtools/).
In order to test if observed differences in the association of OCT4 and
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NANOG with p53-Differentiation is significant, randomized binding sites
showing similar distribution in each chromosome were generated 10000 times
and used for determining statistical significance.

2.1.8 Bivalent histone modification analysis
Normalized wiggle files were used to generate histone aggregate plots.
Transcription start site (TSS) of p53 target genes (up or down-regulated based
on microarray data results) was used as the center of the window and each
window was divided into 40 bins of 25bp resolution. Average ratios were plotted
for each category.

2.2

Gene Expression Analysis
Affymetrix U133 Plus2.0 microarrays were performed for each condition

(Pluripotent, +Adr and +RA) in triplicates. Robust multi-array average (RMA)
method was used with default options (with background correction, quantile
normalization, and log transformation) to normalize raw data from batches using
R/Bioconductor‘s

affy

package

(http://www.bioconductor.org/)

[166].

EntrezGene IDs were assigned to the probe-sets using Affymetrix annotation
package (hgu133plus2.db) in Bioconductor. For genes, which are represented
by multiple probes on the array, maximum expression value was retained for
further analyses. A gene is called as differentially expressed if FDR corrected pvalue is less than 0.05, which is calculated with empirical Bayes method by
eBayes function in Bioconductor’s limma package [167]. Gene Ontology
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analysis of differentially expressed gene was performed using DAVID
(http://david.abcc.ncifcrf.gov/). Volcano plot is generated by using R’s plot
function,

whereas

the

bar

plots

were

(http://ggplot2.org/) package.
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generated

by

using

ggplot2

CHAPTER 3 RESULTS
3.1

Genome wide mapping of p53 in hESCs reveal distinct

functional binding sites
We mapped p53 occupancy throughout the genome using ChIP-Seq
method by deep sequencing of p53-bound chromatin fragments isolated from
hESCs in a pluripotent state (untreated), undergoing differentiation (+RA) or
after DNA damage (+Adr) in order to determine the molecular basis for these
signal-specific responses and define a landscape of p53-chromatin interactions
in hESCs. In pluripotent hESCs, p53 is enriched at 4509 genomic sites,
compared to 8282 and 4941 in hESCs undergoing differentiation or damage,
respectively (Figure 4). We found that p53 is enriched at distinct loci during
each of these different conditions, since intersection of obtained enriched sites
demonstrated that only a fraction of p53-bound peaks (26.5%) overlapped in
between differentiation and damage induction (Figure 4). Comparison of unique
sites in a gradually increasing genomic window revealed that only 44% of
unique sites in differentiation and damage overlapped in a 100kb window,
suggesting highly diverse p53 functions in these two states (Figure 5).
We investigated the evolutionary importance of identified p53-binding sites
by profiling PhastCons score around those sites. Comparing genomic regions
within 4kb of each p53-peak summit in 44 vertebrate species, revealed high
evolutionary conservation of p53 binding regions suggesting potential regulatory
functions of obtained genomic regions in each condition (Figure 6).
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Differentiation

Damage

5550
1639

2653

557
536

92

3324

Untreated

Figure 4. Genome-wide mapping demonstrated unique p53 signatures in
hESCs after different treatments

Comparison of genome occupancy of p53 in untreated, differentiation (RA
2days) and damage (Adriamycin: Adr 6h) induced hESCs. p53 binding sites
identified by peak calling program MACS with p-value 10-8.
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31%
69%

46%

54%

44%
56%

Figure 5. Condition specific binding sites of p53 are strikingly distant

Frequency of overlap between unique sites is shown as a function of distance
between binding sites. Pie charts show percent overlap between unique sites in
100kb distance. Poor overlap of unique sites in differentiation and damage was
observed (44%) even in a 100kb window.
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Figure 6. p53 binding regions are evolutionary conserved among
vertebrates.

Average PhastCons score profiles depicting conservation in the vicinity of p53
binding sites and randomly generated genomic loci (purple).
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3.2

p53 binding sites are enriched for p53 and OCT4:SOX motifs in

differentiation
Motif analysis revealed that p53-bound regions were significantly enriched
with consensus p53 binding sites (p53-motif) in both differentiation and damage
(P < 10-35 and P < 10-235, respectively), a motif that is similar to the p53
consensus obtained from TRANSFAC database (Figure 7A). However,
sequences bound by p53 in pluripotent hESCs (untreated) did not match the
consensus p53-motif significantly (P > 10-5), suggesting signals that activate
p53 in hESCs stabilize p53-chromatin interactions, as a result precipitating
precise p53-bound regions is challenging and yielding an ambiguous signal
across the genome. These results support proposed models of p53 scanning
along DNA, prior to inductive signaling, in a gene-specific manner that
determines downstream response [168].
Intriguingly, p53-bound regions in hESCs undergoing differentiation were
significantly enriched in core transcription factors OCT4 and SOX2 binding
motifs (P < 10-16 and P < 10-12 respectively) (Figures 7A-B), whereas no OCT4SOX2 motifs were found in p53-bound genomic regions from pluripotent hESCs
or those exposed to damage (Figures 7A-B). We performed a reciprocal
analysis to detect any p53-motif within OCT4-SOX2 and NANOG enriched sites,
using previously published ChIP-Seq datasets [134]. Our analysis revealed
overlapping p53 response elements (p53REs) in both OCT4-SOX2 and
NANOG datasets (Figure 8). The presence of consensus binding motifs for
OCT4 and SOX2 in p53-bound regions suggests a possible interplay between
these transcription factors in determination of specific stem cell states.
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Pou5f1(OCT4)
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------

Figure 7. p53, OCT4-SOX2 motifs are enriched within p53 enriched sites

A) p53 and OCT4 consensus motif sequence from TRANSFAC database [top],
and matching enriched motifs under p53 peaks [bottom].
B) The OCT4 motif is enriched in p53-bound regions in cells undergoing
differentiation, but not in response to damage.
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p53 motif in OCT4 bound regions

p53 motif from TRANSFAC database

p53 motif in NANOG bound regions

Figure 8. p53 motif is present in the genomic regions bound by OCT4 and
NANOG

Detected p53 motif in OCT4 (left-up) and NANOG (left-down) bound regions in
pluripotent ES cells. p53 consensus binding motif in TRANSFAC database
(right).
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3.3

p53

targets

developmental

transcription

factors

during

differentiation
Across the genome, a significant portion of p53 binding sites (42% for +RA
and 28% for +Adr) are enriched (0.68 fold for +RA and 0.61 fold for +Adr over
randomized binding sites) within 10kb of the nearest annotated transcription
start site (TSS) (Figure 9A). Therefore, we used a 10kb window of distance
from the p53-peak summit to the nearest gene TSS to call a p53 target gene
(Figure 9B).
Similar to the identified binding sites between conditions, target-gene
comparison analysis revealed only 22% overlap in identity (717 genes) between
damage (1326 genes) and differentiation (3172 genes) (Figure 9B), suggesting
distinct roles for p53 dependent on cellular environment. Gene-ontology (GO)
analysis revealed a startling distinction between genes regulated by p53 during
differentiation versus damage (Table 2). While most of the p53-targets during
differentiation are categorized primarily as genes involved in development
(particularly in neuronal development, a pathway which is triggered by the RA
signaling) and transcription regulation (P < 10-6), damage-specific p53-targets
are associated with cell migration and motility (P < 10-4) (Table 2). Highly
studied p53 targets, e.g., CDKN1A, MDM2, are significantly (P < 10-6)
represented in genes common to both differentiation and damage (Table 2).
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Figure 9. p53 targets distinct set of genes during differentiation and DNAdamage in hESCs
A) Distribution of p53 occupied regions relative to the nearest annotated TSS in
hESCs undergoing differentiation or damage.
B) Numbers of distinct and overlapping p53-target genes in hESCs undergoing
differentiation and DNA damage.

42

Differentiation Specific Target Genes
Identifier
GO:0045449
GO:0048598
GO:0030182
GO:0007389
GO:0030900

GO Term

Genes in
the List

Total
Genes

452
73
94
64
42

2601
307
438
267
152

regulation of transcription
embryonic morphogenesis
neuron differentiation
pattern specification process
forebrain development

P-value
1.56E-12
3.49E-07
9.40E-07
1.50E-06
3.16E-06

Damage Specific Target Genes
Identifier
GO:0016477
GO:0051674
GO:0048870
GO:0006928
GO:0007266

GO Term

Genes in
the List

Total
Genes

21
22
22
29
7

276
307
307
475
38

Genes in
the List

Total
Genes

61
61
13
61
39

804
812
54
815
430

cell migration
localization of cell
cell motility
cell motion
Rho protein signal transduction

P-value
3.10E-04
4.78E-04
4.78E-04
6.52E-04
9.29E-04

Overlapping Target Genes
Identifier
GO:0042981
GO:0043067
GO:0008629
GO:0010941
GO:0043065

GO Term
regulation of apoptosis
regulation of programmed cell death
induction of apoptosis by intracellular signals
regulation of cell death
positive regulation of apoptosis

P-value
4.67E-07
6.42E-07
6.91E-07
7.29E-07
1.39E-06

Table 1. Response specific target genes are involved in different
biological process
GO term analysis revealed significant and diverse functions of p53 downstream
target genes that are specific or shared in response to each treatment
(differentiation and damage).
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Next, we determined enrichment of protein domains encoded by p53target genes in each condition using InterPro terms of the GREAT functional
annotation tool. Homeobox domains were revealed as differentiation targets (P
< 10-13). This finding is consistent with the GO-term analysis results since the
proteins encode Homeobox domains are evolutionary conserved and
developmentally important transcription factors with the ability to bind DNA
through their Homeobox domains. On the other hand, EGF-type domains were
targeted in damage (P < 10-6) (Table 3), currently this domain’s significance
remains to be known because of its presence in protein families what seems to
be unrelated.
Several transcription factor families that regulate specification and
development are highly represented as differentiation targets (Figure 10).
These include members of the Homeodomain-box (HOX) gene family, which
are activated as a first response to RA and regulate pattern formation during
embryogenesis [96]; LIM homeobox (LHX) genes, which are involved in
embryonic development and specifically neuronal differentiation [169]; the
forkhead box (FOX) family of genes, which are involved in axial patterning and
tissue development from all three germ layers [170]; the sex determining
region-Y box (SOX) gene family that regulates cell-fate specification [171]; and,
Zic family members (ZIC) that are important during neuronal development,
mutations of which cause a wide variety of congenital malformations [172]
(Figure 10). These findings suggest that, during differentiation of hESCs, the
regulatory influence of p53 is extensive and amplified by targeting transcription
factors that promote a committed cellular state.
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Enriched protein domains in Differentiation targets
Identifier
IPR009057
IPR012287
IPR001356
IPR017970
IPR020479

INTERPRO Term-Name
Homeodomain-like
Homeodomain-related
Homeobox
Homeobox, conserved site
Homeobox, region

Genes in
the List

Total
Binomial
Genes FDR Q-value

109
106
93
79
40

314
304
237
183
87

7.62E-19
8.81E-19
2.26E-17
8.72E-16
1.65E-13

Enriched protein domains in Damage targets
Identifier
IPR001881
IPR013091
IPR013032
IPR000152
IPR018097

INTERPRO Term-Name
EGF-like calcium-binding
EGF calcium-binding
EGF-like region, conserved site
EGF-type aspartate/asparagine hydroxylation site
EGF-like calcium-binding, conserved site

Genes in
the List
30
25
41
28
27

Total
Binomial
Genes FDR Q-value
108
87
197
102
99

7.56E-07
1.29E-06
3.23E-06
6.64E-06
8.63E-06

Enriched protein domains in Overlapping targets
Identifier
IPR020465

INTERPRO Term-Name
Tumour necrosis factor receptor 10

Genes in
the List
4

Total
Binomial
Genes FDR Q-value
4

1.11E-03

Table 2. Significant number of p53 targets during differentiation possess
homeobox domain
Enrichment analysis of protein domains encoded by p53 downstream target
genes that are specific or common in differentiation and DNA-damage. Top
categories from each dataset are listed.
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Figure 10. Developmental transcription factor families are targeted by p53
during hESC differentiation

Gene families of developmental transcription factors are targets of p53 during
differentiation. p53 (green circle) regulation is linked to individual transcription
factors (cyan circles), shown grouped by family.
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3.4

p53 binding sites coincide with ESC transcription factors

during differentiation
Developmental genes are often poised in ESCs by core pluripotency
factors and bivalent histone modifications [35,36,37,38]. In addition, our motif
analysis revealed that OCT4 and NANOG motifs are enriched at differentiationinduced p53 binding sites but not in DNA damage binding sites. Therefore, we
analyzed the distribution of p53 binding sites, across four representative HOX
loci of the human genome and compared them to OCT4, NANOG and
H3K27me3 enrichment sites (Figure 11). A circular plot of human chromosomes
2, 7, 12 and 17, representing a ~100 Kb region of each HOX cluster, illustrates
enrichment of OCT4, NANOG and H3K27me3 in pluripotent hESCs (Figure 11).
During differentiation p53 binds (21 binding sites to 11 identified target genes)
in and around these HOX clusters. In contrast, there is only one intergenic p53bound site induced by DNA damage at these loci. These findings suggest that,
during differentiation of hESCs, the regulatory influence of p53 is extensive and
amplified by targeting transcription factors that promote a committed cellular
state.
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Figure 11. Binding profiles of p53, OCT4 and NANOG around human HOX
loci

Circos plot of four human HOX gene clusters showing differential binding
patterns of OCT4 (blue), NANOG (red), H3K27me3 (green) in pluripotent
hESCs and p53 (damage:yellow, differentiation:orange)
differentiation:orange).
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Overlap between core transcription factors and differentiation-induced p53
binding sites around the HOX clusters lead us to investigate whether binding
sites of mentioned factors overlap in a region specific or genome-wide fashion.
Obtained results indicated that overlap between p53, OCT4 and NANOG
binding sites is widespread across the genome, as ~50% of the 1000 highest
confidence, differentiation-bound p53 sites are occupied by OCT4, NANOG or
both in pluripotent hESCs; only a small fraction (~12%) overlap with damagespecific p53 sites (Figure 12A). Randomization tests demonstrated that
percentage of differentiation-induced p53 binding sites that overlap with OCT4
and/or NANOG sites is significantly higher than those observed with randomly
generated genomic sites, whereas overlap between damage-specific p53 sites
and OCT4 or OCT4:NANOG binding sites are within random range (Figure
12B). We extended co-occupancy analysis to genome-wide by ranking each
set of p53-binding sites (differentiation- and damage-induced) based on their
enrichment scores and performed the intersection analysis for each segment.
Results showed a significantly higher ratio of p53:OCT4:NANOG overlap and
stronger p53-peaks at differentiation- versus damage-induced binding sites
(Figures 13-14).
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Figure 12. p53 binding sites coincide with ESC transcription factors
during differentiation
A) Overlap of top p53 binding sites with OCT4 and NANOG in hESCs
undergoing differentiation or damage.
B) Plots indicate percent overlaps along the xx-axis,
axis, solid curve represents
expected overlap with random data.
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Figure 13. Association of OCT4 and/or NANOG binding sites with p53

Percent overlap among OCT4, NANOG and enrichment based top ranked p53
bound regions in hESCs undergoing damage (left) or differentiation (right).
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In order to compare the raw signal intensities we performed heat map
analysis, which revealed that ChIP-Seq signal intensity of OCT4 and NANOG at
genomic sites bound by p53 exclusively during hESC differentiation is notably
higher than their signals around p53-damage specific sites (Figure 14A). This
suggests that a specific subset of genes (mostly developmental transcription
factors) is kept in a repressed state by OCT4/NANOG during pluripotency and,
in response to RA, p53 occupies nearby to regulatory regions of these genes to
promote hESC differentiation.
Binding profiles and comparison of p53 and NANOG peaks reveal that
OCT4 enrichment at p53 peaks, established during differentiation, is of the
same magnitude as at NANOG sites (Figure 14B). However, NANOG
enrichment is stronger at OCT4 binding sites than p53 (Figure 14C). The
absence of OCT4 or NANOG at damage-induced p53 sites suggests that p53
plays distinct regulatory roles in hESCs, which are dictated by external stimuli.
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Figure 14. NANOG and OCT4 binding strengths are much higher at
differentiation specific sites

Heat map of binding signals of p53 (damage and differentiation), OCT4 and
NANOG within -500bp to +500 bp of p53 condition-specific peak summits.

53
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Figure 14. NANOG and OCT4 binding strengths are much higher at
differentiation specific sites
Aggregate plots shows average OCT4 (B) and NANOG (C) enrichment profiles
around central position of p53 (Damage:green, Differentiation:Red) and
NANOG/OCT4 (Purple) binding regions.
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3.5

Transcription of development genes is dependent on p53
To uncover the functional consequences of p53 interactions with

chromatin, we performed microarray-based gene expression analysis of hESCs
undergoing differentiation and integrated these data with our p53 ChIP-Seq
dataset (Figure 15). Expression analysis revealed a total of 1220 up- and 1221
down-regulated genes (with FDR-corrected p-value less than 0.05) during
differentiation of hESCs compared to pluripotent state. Intersection with our p53
ChIP-Seq data revealed that more than 25% of genes regulated during
differentiation (262 down- and 361 up-regulated) are bound by p53. We next
sought to identify differentiation-specific p53 targets by eliminating genes that
are targeted by p53 during DNA damage, as a result 198 down- and 271 upregulated genes were assigned as p53’s differentiation-specific targets and
further analyses performed on this set of genes (Figure 15).
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Figure 15.. Integration of gene expression and p53 binding data in
differentiating hESCs

Volcano plot of microarray gene
gene-expression
expression data. Each point corresponds to
RefSeq gene; in RA treated samples with average log2 fold change compared
to pluripotent hESCs and negative log10 p- value scores. Colored points
correspond to genes bound by p53: significantly up
up- (red) or downdown regulated
(green) p53 targets are highlighted. Target genes overlapping with damage
datasets are discarded.
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GO-term analysis of RA-down-regulated p53 targets revealed that these
genes are enriched for cell motion and mesodermal differentiation (Figure 16).
These genes include FOXO3: essential activator of mesodermal marker
Brachyury [173]; KLF6: associated with hematopoiesis [174]; chromatin
modifiers HDAC5 and HDAC9: class II HDACs with critical functions in heart
development [175]; and, telomere repeat binding factor TERF1: a telomere
maintenance factor associated with pluripotency [176] (highlighted in Figure 15).

Untreated

Differentiation

Regulation of cell motion

Lymphocyte differentiation

Negative regulation of biosynthetic process

Regulation of transcription

B cell differentiation

-log10(p-value)

log2(fold change)

Figure 16. GO functional classifications of down-regulated p53

Heat map, generated for differentiation-specific p53 target genes, reveals up- or
down-regulated targets during differentiation compared to pluripotent hESCs.
The GO-term analysis of down-regulated p53-target genes is shown.
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RA-up-regulated p53 targets revealed significant (P<10-5) representation
in neuro-ectodermal development, embryonic morphogenesis and pattern
specification categories (Figure 17). These genes include homeobox domain
genes (HOXA1, HOXA3, HHEX and HOXB1), developmental transcription
factors (GATA2, LHX8, ZIC1 and TCF7L2) and RA nuclear receptors (RARA
and RARB) (highlighted in Figure 15). Several of these genes are repressed by
Polycomb complexes and poised by core pluripotency factors in pluripotent
hESCs [17], but a role for p53 in their activation during differentiation has not
previously been reported.

Untreated

Differentiation
Pattern specific process
Embryonic morphogenesis
Embryonic organ development
Regulation of nervous system development
Endocrine system development
Regulation of neurogenesis
Regionalization
Regulation of cell development
Positive regulation of gene expression

log2(fold change)

-log10(p-value)

Figure 17. Up-regulated p53 targets are involved in developmental
processes
Heat map, generated for differentiation-specific p53 target genes, reveals up- or
down-regulated targets during differentiation compared to pluripotent hESCs.
The GO-term analysis of up-regulated p53-target genes is shown.
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We performed quantitative RNA and p53 ChIP-PCR analyses of selected
genes (Figure 15), to assess the impact of p53 binding and to validate the
outputs of our genome-wide assays (Figures 18-19). RA treatment for 2 and 4
days resulted in significant activation of genes belonging to HOX and GATA
families (Figure 18A). Four days of RA increased expression of these genes, as
well as developmental transcription factors: TBX5, homeobox genes MSX2 and
GBX2, hedgehog receptor PTCH1, Notch co-repressor TLE3, polycomb protein
BMI1 and histone H3K36 demethylase KDM2B (Figure 18B). Observed
differences in the timing of target gene inductions may be due to a cascade of
transcriptional events, where certain genes are activated as early as two days
during RA-mediated hESCs differentiation, whereas it takes others longer to be
induced.
RA-mediated transcriptional activation of selected genes is dependent on
p53, since hESCs transfected with siTP53 showed no significant activation of
these genes with RA-treatment. In contrast, p53 induction by DNA damage had
no significant effect on these genes (Figures 18A-B). Expression of well-known
p53 pathway genes CDKN1A and MDM2 was induced during both
differentiation and damage in a p53-dependent manner, confirming the GO
analysis results (Table 2) which indicated that p53-pathway genes are enriched
in the shared targets under these two conditions. (Figure 18C).
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Figure 18. Transcription of developmental genes during RA-mediated
differentiation is p53-dependent
RT-qPCR analyses of selected genes in hESCs after 4 d of RA-treatment with
TP53 or control non-targeting siRNA. Error bars represent standard deviation
from three replicates (* <0.05, ** <0.01). [data contributed by Abhinav Jain]
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We used positional weight matrixes (PWMs) obtained from transcription
factor motif analysis (Figures 7-8) of p53-enriched genomic regions to map
OCT4, NANOG and p53 binding elements at specific developmental genes:
HOXA1, PTCH1 and TBX5 (Figure 19A). ChIP-qPCR analyses revealed robust
enrichment of p53 binding, within two days of RA exposure, at the p53REs of
PTCH1, HOXA1, TBX5 and CDKN1A (Figure 19B). Importantly, p53enrichment at these sites (PTCH1, HOXA1 and TB5) is RA-specific, since no
significant changes observed in response to DNA-damage. On the other hand,
in both conditions p53 enriched around the CDKN1A promoter, this suggests
that developmental gene targeting is specific to p53’s role in hESC
differentiation (Figure 19B).
To assess whether OCT4 and p53 co-occupy the overlapping binding sites,
we performed sequential ChIPs (re-ChIP) on OCT4-enriched chromatin
fragments from hESCs treated with RA for 2 days (Figure 19C). RA robustly
induced p53 enrichment and co-occupancy at OCT4-associated regions of
PTCH1 and TBX5, roughly equivalent to the increase in p53 association
induced by RA (Figure 19C). The OCT4-OCT4 re-ChIP indicates equal
efficiency of OCT4 binding to chromatin sites in both untreated and 2-day RAtreated hESCs. However, the distance between p53 and OCT4 binding sites on
HOXA1 (> 500bp) is greater than the vast majority of our fragmented chromatin
length (Figure 19A) that’s why re-ChIP experiments was not feasible for this
genomic locus.
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Figure 19. Enrichment of p53 at developmental genes results in activation
A) Tracks represent normalized p53 sequence tag enrichments (numbers
indicate distance from TSS). Binding location of NANOG (red) and OCT4 (blue)
are shown at the bottom of the tracks.
B) ChIP-qPCR analysis of p53 occupancy at select target genes during
differentiation [top] or DNA damage [bottom]. [data contributed by Kendra Alton]
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Developmental genes are held poised in ESCs by repressive histone
marks (H3K27me3), which are lost upon differentiation [2]. We generated
hESCs stably expressing non-target (shControl) or shRNA against p53
(shTP53) to determine whether RA-activated p53 had an impact on levels of
H3K27me3 at the promoters and/or p53-response elements (p53RE) of PTCH1,
TBX5 where p53 co-localizes with OCT4 at 2 days of RA treatment (Figure
19C). Stable integration of shTP53 resulted in a significant knockdown of p53
protein and failure to elicit an RA-response, since no reduction in AP-staining
and OCT4 protein was observed in shTP53-hESCs as compared to control
(data not shown). In response to RA, H3K27me3 levels are significantly
reduced at PTCH1 and TBX5 in shControl cells, whereas no change in
H3K27me3 levels were observed in hESCs stably depleted of p53 (shTP53)
(Figure 19D).
Together, these results suggest that RA-induced signals of differentiation
mobilize p53 to bind and activate a number of chromosomal locations around
the developmentally important transcription factors that are poised by
OCT4/NANOG in pluripotent hESCs by altering the chromatin status.
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Figure 19. Enrichment of p53 at developmental genes results in activation.
C) p53 enrichment on OCT4 bound regions after sequential ChIPs. Quantitative
PCR of chromatin fragments enriched by p53, OCT4 and sequential ChIP of
hESCs, treated with RA for 2 days. DNA enrichments at indicated target genes
were determined as fold change in % input, compared to untreated hESCs.
D) Histone H3K27me3 status on gene promoter or p53RE of PTCH1 and TBX5
in hESCs treated with RA for 2 days. Error bars represent standard deviation
from three replicates (* <0.05, ** <0.01). [data in Figs 19C-D contributed by
Kendra Alton]
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3.6
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We next sought to determine if changes in bivalent chromatin structure
occur globally around the p53-target genes during differentiation, by analyzing
genome wide histone status utilizing ChIP-Seq method for active (H3K4me3) or
repressive (H3K27me3) histone marks in hESCs undergoing differentiation. To
define histone tail modifications at the promoters of p53 targets, we first
categorized the p53’s differentially expressed targets as those that have
overlapping OCT4 and/or NANOG binding sites, and the ones that are targeted
by p53 only (Figures 21-22). Gene expression profiling revealed that while the
average expression of the two sets are comparable, p53 gene targets that are
shared with those bound by OCT4 and/or NANOG prior to differentiation are the
most significantly changed (up- or down-regulated) genes (Figures 21A and
22A). Consistent with the biological functions of all differentiation-specific p53targets (Table 2), GO-term analysis for up-regulated p53 targets with
overlapping OCT4 and/or NANOG sites revealed genes responsible for pattern
specification, embryonic morphogenesis and development (Figure 20B).
On the other hand, down-regulated p53 targets with overlapping OCT4
and/or NANOG sites are involved in mesodermal differentiation, metabolism
and cell motion (Figure 21B).
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Figure 20. p53’s overlapping targets with OCT4 and NANOG are more
robustly expressed during differentiation
A) Violin plots representing fold changes in expression of p53 targets upregulated during differentiation. Genes that have p53 binding sites overlapping
with OCT4 and/or NANOG (p53_OCT4_NANOG) (blue); or only p53 binding
sites (green).
B) The GO-Term analysis of overlapping targets of p53_OCT4_NANOG is
shown.
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Figure 21. GO functional classification results down-regulated p53 targets
with overlapping OCT4 and/or NANOG sites
A) Violin plots representing fold changes in expression of p53 targets downregulated during differentiation. Genes that have p53 binding sites overlapping
with OCT4 and/or NANOG (p53_OCT4_NANOG) (blue); or only p53 binding
sites (green).
B) The GO-Term analysis of overlapping targets of p53_OCT4_NANOG is
shown.
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Genome wide profiling of average histone modifications confirmed that
up-regulated p53-targets, overlapping with OCT4 and/or NANOG sites, are
associated with bivalent histone marks (H3K4me3 and H3K27me3), which are
significantly altered during differentiation (high H3K4me3, low H3K27me3), as
compared to down-regulated targets (Figures 22A and 22C). However, genes
targeted by p53 only gain H3K4me3 marks without a significant change in
H3K27me3 status (Figures 22B and 22D).
Taken together, these results suggest that p53 plays an active role,
possibly cooperating with core pluripotency factors, during differentiation of
hESCs by recruitment of chromatin modifying complexes, which decrease
repressive histone marks of specific developmental genes held poised in
pluripotent stem cells.
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Figure 22. Bivalent chromatin marks around promoter regions of p53
target genes in pluripotent and differentiating hESCs
Aggregate plots showing profiles of histone modifications around +/- 2KB from
transcription start site (TSS) of up-regulated p53_OCT4_NANOG overlapping
gene targets (A) and only p53 targets (B).
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Figure 22. Bivalent chromatin marks around promoter regions of p53
target genes in pluripotent and differentiating hESCs.
Aggregate plots showing profiles of histone modifications around +/- 2KB from
transcription start site (TSS) of down-regulated p53_OCT4_NANOG
overlapping gene targets (A) and only p53 targets (B).
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CHAPTER 4 DISCUSSION AND FUTURE DIRECTIONS
4.1 Discussion
Studies of p53 are extensive; specifically its functions in cell cycle
regulation and apoptosis have been scrutinized for several decades in
transformed somatic cells [115,177,178]. The broader potential in regulatory
roles of numerous cellular processes was only recently appreciated. For an
example, p53 has been implicated in regulating cellular metabolism,
deregulation of p53 leads to compromised oxidative phosphorylation chain,
which is also known as Warburg effect, one of the hallmarks of cancer cells
[179,180].
On the other hand, a limited knowledge of p53’s function in nontransformed cells; especially in highly proliferative undifferentiated cells, such
as embryonic stem cells, therefore its role in development and control of cellfate is largely unknown [116]. In order to dissect p53’s functions during
transcription in human ESCs cultured under different culture conditions
(Adriamycin for DNA damage and RA for differentiation), we performed
genome-wide p53-chromatin binding assays along with gene expression
microarrays. Integration of the data output from these comprehensive methods
revealed that the RA-mediated p53-response during differentiation is highly
distinct from the stress-responsive events occurring downstream of DNA
damage in hESCs. During early differentiation, p53 activates the expression of
several developmental transcription factor families, many of which possess
homeobox protein domains. This activated cascade of transcription factors
71

amplifies the functional effects of p53 induction beyond the transient time period
when p53 protein is elevated [140].
Differentiation-specific p53-activated genes include members of HOX,
FOX, SOX, T-box (TBX) and Chromobox (CBX) gene families that are involved
in differentiation and development. HOX genes are known to be involved in
patterning during embryogenesis as major developmental factors [181], for
example HOXA1 is essential for RA-mediated neural differentiation [98]. FOX
family members have been implicated in formation of different organs during
development [170], such as liver. Mutations in SOX family genes impair proper
differentiation and have been related to several developmental disorders [171].
Members of the CBX family, particularly CBX2 and CBX4 are part of the
Polycomb complex [182] and are vital for cell-fate determination [172]; whereas
the TBX gene family regulates a diverse range of developmental processes
from early body planning to late organogenesis [183].
One facet of p53 gene regulation involves repression of some
transcription factors and epigenetic modifiers while activating another set of
developmental genes required for RA-mediated neuro-ectodermal lineage
specification. Some of the down-regulated p53 targets include regulators
required for mesodermal lineage specification such as, transcription factors
FOXO3 [173], HEY1 [184] and KLF6 [174]; histone deacetylases HDAC5,
HDAC6 [175] and chromatin remodeler CHD7 [185]. Several proteins that are
involved in transcriptional repression are also targeted by p53 for downregulation including telomere repeat factor TERF1 [176], PcG complex
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compotent RNF2 [186] and Chromobox family member CBX5 [187]. Taken
together, p53 might play a significant role in lineage determination by RAinduced p53-mediated repression and activation of specific genes in hESCs.
Remarkably, our motif finding analysis revealed that the differentiationspecific p53-bound sites are also enriched in OCT4:SOX2 motif. Moreover,
comparison of binding sites showed that more than half of the strongest p53bound sites are coincident with binding sites of core pluripotency factors OCT4
or NANOG, or both, in pluripotent hESCs. This suggests that there could be
interplay between p53 and the core pluripotency factors, specifically during
early hESC differentiation since this phenomenon is not observed for p53’s
binding sites during DNA-damage. Our experimental validations showed that
three developmental genes HOXA1 [98], PTCH1 [188] and TBX5 [189] are upregulated during hESC differentiation in a p53-dependent manner. Chromatin
immunoprecipitation (ChIP) studies revealed that OCT4 and NANOG are bound
at or in the proximity of p53-binding sites at these developmental genes during
differentiation. Sequential-ChIP assay confirmed that during differentiation p53
indeed co-localizes to these regions, which are bound by OCT4. However, our
current findings cannot conclude whether p53 recruitment ultimately results in
displacing the bound OCT4 and/or NANOG proteins at the regulatory sites or
these factors synergistically bring other chromatin modifiers to those loci,
thereby activating down-stream targets expression. Elucidation of the exact
mechanism requires further experiments.
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Given the importance of bivalent domains in pluripotency maintenance
and establishment of cell fate [35,36,37,38], we profiled the bivalent histone
modifications (H3K4me3 and H3K27me3) in pluripotent and differentiating
hESCs by ChIP-Seq. Our analyses revealed that up-regulated p53 targets,
which are also bound by OCT4 and/or NANOG, are kept poised in ESCs by
bivalent modifications and during differentiation promoter regions of these
genes acquire more H3K4me3 mark while losing their H3K27me3 modifications.
Furthermore, we tested if p53 has any roles regulating the chromatin
modification switch near its target genes during differentiation. Notably, PTCH1
and TBX5 gene promoters could not lose their promoter-associated H3K27me3
marks during differentiation in p53-depleted hESCs. These results suggest that
p53 might play a significant role in modifying chromatin structure at its poised
target genes by coupling with an unknown H3K27 demethylase complexes
during hESC differentiation.
The shared target genes of p53 during differentiation and DNA damage
response are enriched in cell cycle regulation. p53-regulated cell-cycle control
pathways play significant roles in both during hESC differentiation, by impeding
cell cycle and leading differentiation [140], and DNA-damage repair by blocking
the self-renewal pathway in order to prevent accumulation of chromosomal
damage. Metabolism, another common GO term for conserved p53 target
genes, suggests the link between p53 and metabolism could be as crucial as
cell cycle pathways during both development and tumor suppression [179,190].
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The most interesting GO terms that are identified specifically in p53
targets during DNA-damage, cell motion and cell migration, are the signature
characteristics of metastatic carcinomas. For example, damage specific p53
gene targets listed under GO category of cell motion, FGF2 and LRP8, have
been grouped into the stem-like gene expression sets that are only observed in
p53 loss-of function cancers [126]. Moreover, two other cell motion-associated
p53 targets, MMP14 and TNFRSF12A, are classified in epithelial to
mesenchymal transition (EMT), which is a required step for metastasis [191],
genes in prostate cancers [126]. Further examination of DNA-damage specific
targets provides an opportunity to dissect profiles of aggressive metastatic
tumors by monitoring changes in activities of these genes as an indication of
deregulated p53-pathway.
Our study unveiled p53’s important regulatory functions in the human
embryonic differentiation, which does not align with the previously reported
findings about p53’s role in mESCs. Previous reports have shown that p53
binds to the promoter of Nanog in mESCs and suppresses its transcription,
which leads to differentiation of mESCs [131]. Instead, we did not detect any
p53 binding sites nearby NANOG regulatory regions in our p53 ChIP-Seq
results in hESCs. Secondly, Li et al. recently reported that in response to DNAdamage p53 both activates differentiation-associated genes and represses ESspecific genes in mESCs [133]. However, our results in hESCs indicate that p53
targets a different set of genes during differentiation versus DNA-damage and
only differentiation-specific p53 target genes are related with development and
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specification. These findings implicate that unlike mouse ESCs, p53 does not
repress pluripotency factors in human ESCs, yet only mediate expression of
developmental genes. Moreover, p53’s pro-differentiation role takes place
under different environmental conditions (DNA-damage in mouse and
differentiation-initiation in human ESCs) in different species (Figure 23, p53
targets several Hox genes upon DNA-damage in mESC but binds to only a
single intergenic region in human HOX cluster loci after exposed to the same
stress in hESCs). Observed species-specific differences in p53’s functions in
two organisms may be attributed to the different embryonic development stages
of mouse and human ESCs [192]. In parallel, mounting evidences demonstrate
a rapid evolutionary turnover for transcription factor binding sites on a genomewide scale between species which results in regulation of a diverse set of
genomic elements in different species by the same transcription factor
[134,193,194,195,196].
Given the p53’s significant role in promoting hESCs differentiation,
viability of p53-null mice and formation of teratomas in SCID mice from p53-null
hESCs raises some interesting questions [197]. In this case, we believe
compensation of p53 functions in development would likely to be executed by
the structurally related protein family members, p63 and p73 [198]. Notably,
several developmental abnormalities such as neural tube malformations or
defects in spermatogenesis and embryo implantation have been reported
despite the fact that p53-null mice are not embryonic lethal [116]. This suggests
that p53’s functions are imperfectly compensated by other factors, but whether
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p63 or p73 isoforms target any or all p53 downstream targets in hESCs
differentiation remains to be investigated.
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Figure 23. Species-specific
specific binding of p53 in different environmental stimuli
Human
an (hs) and mouse (mm) HOX gene clusters loci are shown in this circular
plot. Green track represents repressive H3K27me3 mark around the displayed
regions in mESCs and hESCs
hESCs.. Tiles (black, orange or yellow bars) show
underlying structures of HO
HOX genes. Red (DNA-damage)
damage) and
a
blue
(differentiation) rectangles represent enriched p53 binding sites in these two
conditions. Purple heatmap shows the PhastCons scores around the displayed
displ
regions. Ribbons show synt
syntenic
enic genomic locations between mouse and human
(orange ribbons presents homologous p53 binding sites between DNADNA
damaged mESCs and differentiating hESCs, whereas yellow ribbons are for
shifted sites for same gene targets in mESCs and hESCs).
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4.2 Future Directions
Our mapping results revealed that for both DNA damage and
differentiation of hESCs, p53-binding sites are enriched mostly in intergenic
regions of the genome where non-coding RNA expression initiates (more than
50% of total binding sites in DNA damage and differentiation are located in
gene desert regions). Binding sites of p53 around these intergenic sites gain
significant value when the recent reports about ncRNAs (lncRNAs and miRNAs)
and their effects in pluripotency and differentiation are taken into consideration
[62]. Additional studies are required to confirm p53’s regulatory significance in
regulation of ncRNAs expression and possible down-stream roles of those p53regulated RNAs in hESCs differentiation.
Members of p53 family, p63 and p73, can also regulate the geneexpression program that is mainly directed by p53, in which p73 had been
shown to serve as a back-up protein for maintaining genomic integrity when p53
functions are compromised [199]. These proteins are also implicated in
important developmental processes [200] such as p63 in epithelial ESC selfrenewal [201] and p73 during neural cell differentiation [202]. Notably,
significant portion of amino acids in DNA-binding domains, ~85%, are
conserved among p53 family members, further reports revealed that p63 and
p73 co-occupy target sites with a shared consensus motifs similar to those of
p53 [203]. Therefore, obtaining genome-wide binding maps of p63 and p73 in
differentiating or DNA-damaged hESCs would eventually lead a more
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comprehensive understanding of the roles of this tumor-suppressor protein
family role in human development.
Understanding the differences in regulatory networks for balancing
pluripotency and differentiation between mouse and human ESCs, it would be
important to establish genome-wide p53 binding sites in differentiating mouse
ES and epiblast stem cells. Mouse epiblasts are considered to be more
developmentally close to human ESCs [137,192] and thus determination of
p53’s binding sites will help to understand the regulatory functions of p53 in
development of these two organisms.
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